Keywords
Last Name
Institution

James M. Gallo

TitlePROFESSOR
InstitutionMount Sinai
DepartmentPharmacology and Systems Therapeutics
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Reddy MV, Mallireddigari MR, Pallela VR, Cosenza SC, Billa VK, Akula B, Subbaiah DR, Bharathi EV, Padgaonkar A, Lv H, Gallo JM, Reddy EP. Design, Synthesis, and Biological Evaluation of (E)-N-Aryl-2-arylethenesulfonamide Analogues as Potent and Orally Bioavailable Microtubule-Targeted Anticancer Agents. J Med Chem. 2013 Jul 11; 56(13):5562-86.
      View in: PubMed
    2. Sharma J, Lv H, Gallo JM. Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma. Cancer Res. 2013 Aug 15; 73(16):5242-52.
      View in: PubMed
    3. Tiwari AK, Zhang R, Gallo JM. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Mol Cancer Ther. 2013 Jul; 12(7):1343-55.
      View in: PubMed
    4. Gallo JM. Physiologically based pharmacokinetic models of tyrosine kinase inhibitors: a systems pharmacological approach to drug disposition. Clin Pharmacol Ther. 2013 Mar; 93(3):236-8.
      View in: PubMed
    5. Lv H, Zhang X, Sharma J, Reddy MV, Reddy EP, Gallo JM. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J. 2013 Jan; 15(1):250-7.
      View in: PubMed
    6. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett. 2013 Jan 28; 328(2):307-17.
      View in: PubMed
    7. Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. J Pharmacol Exp Ther. 2012 Nov; 343(2):509-19.
      View in: PubMed
    8. Sharma J, Lv H, Gallo JM. Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model. J Pharm Sci. 2012 Nov; 101(11):4100-6.
      View in: PubMed
    9. Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharm Res. 2012 Sep; 29(9):2499-511.
      View in: PubMed
    10. Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012 Mar 21; 4(126):126ps7.
      View in: PubMed
    11. Lv H, Wang F, Reddy MV, Zhou Q, Zhang X, Reddy EP, Gallo JM. Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs. 2012 Dec; 30(6):2263-73.
      View in: PubMed
    12. Wang Z, Zhou Q, Kruh GD, Gallo JM. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov; 39(11):2155-61.
      View in: PubMed
    13. Nuthalapati S, Guo P, Zhou Q, Reddy MV, Reddy EP, Gallo JM. Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal. 2011 Dec 15; 56(5):1117-20.
      View in: PubMed
    14. Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J. 2011 Mar; 13(1):111-20.
      View in: PubMed
    15. Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, Trapani G. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010 Dec 6; 7(6):2255-69.
      View in: PubMed
    16. Noble W, Hanger DP, Gallo JM. Transgenic mouse models of tauopathy in drug discovery. CNS Neurol Disord Drug Targets. 2010 Aug; 9(4):403-28.
      View in: PubMed
    17. Gallo JM. Pharmacokinetic/ pharmacodynamic-driven drug development. Mt Sinai J Med. 2010 Jul-Aug; 77(4):381-8.
      View in: PubMed
    18. Wang F, Zhou F, Kruh GD, Gallo JM. Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors. Neuro Oncol. 2010 Oct; 12(10):1043-9.
      View in: PubMed
    19. Zhou Q, Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. J Pharm Biomed Anal. 2010 Mar 11; 51(4):958-64.
      View in: PubMed
    20. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009 Oct; 6(10):1017-32.
      View in: PubMed
    21. Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009 Jun; 8(6):1438-47.
      View in: PubMed
    22. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res. 2009 Jan 1; 69(1):120-7.
      View in: PubMed
    23. Zhou Q, Gallo JM. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro Oncol. 2009 Jun; 11(3):301-10.
      View in: PubMed
    24. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res. 2008 Mar 1; 14(5):1540-9.
      View in: PubMed
    25. Wang S, Guo P, Wang X, Zhou Q, Gallo JM. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther. 2008 Feb; 7(2):407-17.
      View in: PubMed
    26. Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res. 2007 Jul 15; 13(14):4271-9.
      View in: PubMed
    27. Gallo JM, Noble W, Martin TR. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. Cell Mol Life Sci. 2007 Jul; 64(13):1701-14.
      View in: PubMed
    28. Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, Mitrophanous K, Chapple JP, Gallo JM, Cheetham ME, Uney JB. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther. 2007 Jun; 15(6):1100-5.
      View in: PubMed
    29. Kruh GD, Belinsky MG, Gallo JM, Lee K. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice. Cancer Metastasis Rev. 2007 Mar; 26(1):5-14.
      View in: PubMed
    30. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007 Apr; 321(1):265-75.
      View in: PubMed
    31. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, Gallo JM. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007 Apr 11; 43(5):1789-95.
      View in: PubMed
    32. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, Gallo JM, Kruh GD. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res. 2007 Jan 1; 67(1):262-8.
      View in: PubMed
    33. Dunlop LC, Cohen J, Harvey M, Gallo J, Motum P, Rosenfeld D. The immature reticulocyte fraction: a negative predictor of the harvesting of CD34 cells for autologous peripheral blood stem cell transplantation. Clin Lab Haematol. 2006 Aug; 28(4):245-7.
      View in: PubMed
    34. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC, Shaw DE, Mazar AP, Cohen RB. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer. 2006 Jun 5; 94(11):1621-6.
      View in: PubMed
    35. Gallo J, Sauer P, Dendis M, Lovecková Y, Kolár M, Zapletalová J, Janout V. [Molecular diagnostics for the detection of prosthetic joint infection]. Acta Chir Orthop Traumatol Cech. 2006 Apr; 73(2):85-91.
      View in: PubMed
    36. Mitsuuchi Y, Powell DR, Gallo JM. Adenoviral modification of mouse brain derived endothelial cells, bEnd3, to induce apoptosis by vascular endothelial growth factor. Oncogene. 2006 Feb 9; 25(6):954-8.
      View in: PubMed
    37. Zhou Q, Gallo JM. In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J. 2005; 7(3):E659-67.
      View in: PubMed
    38. Connell JW, Rodriguez-Martin T, Gibb GM, Kahn NM, Grierson AJ, Hanger DP, Revesz T, Lantos PL, Anderton BH, Gallo JM. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. Brain Res Mol Brain Res. 2005 Jun 13; 137(1-2):104-9.
      View in: PubMed
    39. Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clin Cancer Res. 2004 Dec 1; 10(23):8048-58.
      View in: PubMed
    40. Guo P, Wang X, Zhou F, Gallo JM. Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 5; 809(2):273-8.
      View in: PubMed
    41. de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol. 2004 Aug; 54(2):105-12.
      View in: PubMed
    42. Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Jun; 53(6):513-8.
      View in: PubMed
    43. Benjamin RK, Hochberg FH, Fox E, Bungay PM, Elmquist WF, Stewart CF, Gallo JM, Collins JM, Pelletier RP, de Groot JF, Hickner RC, Cavus I, Grossman SA, Colvin OM. Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol. 2004 Jan; 6(1):65-74.
      View in: PubMed
    44. Guo P, Ma J, Li S, Gallo JM. Determination of paclitaxel in mouse plasma and brain tissue by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Dec 5; 798(1):79-86.
      View in: PubMed
    45. Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 2003 Aug 15; 63(16):5114-7.
      View in: PubMed
    46. Trapani G, Laquintana V, Latrofa A, Ma J, Reed K, Serra M, Biggio G, Liso G, Gallo JM. Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors. Bioconjug Chem. 2003 Jul-Aug; 14(4):830-9.
      View in: PubMed
    47. Ma J, Li S, Reed K, Guo P, Gallo JM. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther. 2003 Jun; 305(3):833-9.
      View in: PubMed
    48. Guo P, Li S, Gallo JM. Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5; 783(1):43-52.
      View in: PubMed
    49. Sun W, Stevenson JP, Gallo JM, Redlinger M, Haller D, Algazy K, Giantonio B, Alila H, O'Dwyer PJ. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res. 2002 Oct; 8(10):3100-4.
      View in: PubMed
    50. Lewis NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemother Pharmacol. 2002 Oct; 50(4):257-65.
      View in: PubMed
    51. Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep; 50(3):243-50.
      View in: PubMed
    52. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol. 2002 Apr 1; 63(7):1219-28.
      View in: PubMed
    53. Ma J, Reed KA, Gallo JM. Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar 1; 62(5):1382-7.
      View in: PubMed
    54. Chong BH, Gallus AS, Cade JF, Magnani H, Manoharan A, Oldmeadow M, Arthur C, Rickard K, Gallo J, Lloyd J, Seshadri P, Chesterman CN. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001 Nov; 86(5):1170-5.
      View in: PubMed
    55. Butler R, Leigh PN, Gallo JM. Androgen-induced up-regulation of tubulin isoforms in neuroblastoma cells. J Neurochem. 2001 Aug; 78(4):854-61.
      View in: PubMed
    56. Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001 Aug; 48(2):169-76.
      View in: PubMed
    57. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001 Jul 15; 61(14):5491-8.
      View in: PubMed
    58. Connell JW, Gibb GM, Betts JC, Blackstock WP, Gallo J, Lovestone S, Hutton M, Anderton BH. Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. FEBS Lett. 2001 Mar 23; 493(1):40-4.
      View in: PubMed
    59. Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, Rogatko A, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RF. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol. 2001 Feb 15; 19(4):1183-94.
      View in: PubMed
    60. Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, Dayanandan R, Gallo JM, Gibb G, Hanger DP, Hutton M, Kardalinou E, Leroy K, Lovestone S, Mack T, Reynolds CH, Van Slegtenhorst M. Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp. 2001; (67):73-80.
      View in: PubMed
    61. Chu J, Gallo JM. Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev. 2000 Dec 15; 45(2-3):243-53.
      View in: PubMed
    62. O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clin Cancer Res. 2000 Dec; 6(12):4692-6.
      View in: PubMed
    63. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res. 2000 Aug; 6(8):3071-80.
      View in: PubMed
    64. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000 Jun; 18(12):2459-67.
      View in: PubMed
    65. Butler R, Robertson J, Gallo JM. Mutually exclusive expression of beta(III)-tubulin and vimentin in adrenal cortex carcinoma SW13 cells. FEBS Lett. 2000 Mar 24; 470(2):198-202.
      View in: PubMed
    66. Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol. 1999 Jul; 17(7):2198-207.
      View in: PubMed
    67. Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol. 1999 Jan; 41(2):99-105.
      View in: PubMed
    68. Chen SH, Gallo JM. Use of capillary electrophoresis methods to characterize the pharmacokinetics of antisense drugs. Electrophoresis. 1998 Nov; 19(16-17):2861-9.
      View in: PubMed
    69. Ma J, Fei ZL, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis. 1998 Aug; 16(6):559-68.
      View in: PubMed
    70. Cleverley KE, Betts JC, Blackstock WP, Gallo JM, Anderton BH. Identification of novel in vitro PKA phosphorylation sites on the low and middle molecular mass neurofilament subunits by mass spectrometry. Biochemistry. 1998 Mar 17; 37(11):3917-30.
      View in: PubMed
    71. Butler R, Leigh PN, McPhaul MJ, Gallo JM. Truncated forms of the androgen receptor are associated with polyglutamine expansion in X-linked spinal and bulbar muscular atrophy. Hum Mol Genet. 1998 Jan; 7(1):121-7.
      View in: PubMed
    72. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target. 1998; 6(3):215-27.
      View in: PubMed
    73. Ma J, Gallo JM. Delivery of cytotoxic drugs from carrier cells to tumour cells by apoptosis. Apoptosis. 1998; 3(3):195-202.
      View in: PubMed
    74. Gallo JM. The ins and outs of antiviral drug transport in the brain. J Neurovirol. 1997 Dec; 3(6):385-6.
      View in: PubMed
    75. DiPaola RS, Weiss RE, Cummings KB, Kong FM, Jirtle RL, Anscher M, Gallo J, Goodin S, Thompson S, Rasheed Z, Aisner J, Todd MB. Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res. 1997 Nov; 3(11):1999-2004.
      View in: PubMed
    76. Qian M, Chen SH, von Hofe E, Gallo JM. Pharmacokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor-bearing nude mice. J Pharmacol Exp Ther. 1997 Aug; 282(2):663-70.
      View in: PubMed
    77. Huhn RD, Radwanski E, Gallo J, Affrime MB, Sabo R, Gonyo G, Monge A, Cutler DL. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther. 1997 Aug; 62(2):171-80.
      View in: PubMed
    78. Gallo JM, Hafeli U. A.S. Lübbe et al., Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res., 56: 4694-4701, 1996; and Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res., 56: 4686-4693, 1996. Cancer Res. 1997 Jul 15; 57(14):3063-5.
      View in: PubMed
    79. Kupczyk-Subotkowska L, Siahaan TJ, Basile AS, Friedman HS, Higgins PE, Song D, Gallo JM. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. J Med Chem. 1997 May 23; 40(11):1726-30.
      View in: PubMed
    80. Chen SH, Qian M, Brennan JM, Gallo JM. Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis. J Chromatogr B Biomed Sci Appl. 1997 Apr 25; 692(1):43-51.
      View in: PubMed
    81. Carter JE, Gallo JM, Anderson VE, Anderton BH, Robertson J. Aggregation of neurofilaments in NF-L transfected neuronal cells: regeneration of the filamentous network by a protein kinase C inhibitor. J Neurochem. 1996 Nov; 67(5):1997-2004.
      View in: PubMed
    82. O'Dwyer PJ, Laub PB, DeMaria D, Qian M, Reilly D, Giantonio B, Johnston AL, Wu EY, Bauman L, Clendeninn NJ, Gallo JM. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct; 2(10):1685-92.
      View in: PubMed
    83. O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, Green F, Gallo JM, Brennan J, Frucht H, Goosenberg EB, Hamilton TC, Litwin S, Balshem AM, Engstrom PF, Clapper ML. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest. 1996 Sep 1; 98(5):1210-7.
      View in: PubMed
    84. Lee KM, Bruckner JV, Muralidhara S, Gallo JM. Characterization of presystemic elimination of trichloroethylene and its nonlinear kinetics in rats. Toxicol Appl Pharmacol. 1996 Aug; 139(2):262-71.
      View in: PubMed
    85. Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH. In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J Neurochem. 1996 Aug; 67(2):699-707.
      View in: PubMed
    86. Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 1996 May 1; 56(9):1983-7.
      View in: PubMed
    87. Laub PB, Gallo JM. NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci. 1996 Apr; 85(4):393-5.
      View in: PubMed
    88. Obasaju CK, Johnson SW, Rogatko A, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res. 1996 Mar; 2(3):549-52.
      View in: PubMed
    89. Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol. 1996; 38(6):499-507.
      View in: PubMed
    90. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 1996 Jan; 14(1):249-56.
      View in: PubMed
    91. Smith CJ, Anderton BH, Davis DR, Gallo JM. Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. FEBS Lett. 1995 Nov 20; 375(3):243-8.
      View in: PubMed
    92. Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res. 1995 Oct 15; 55(20):4507-11.
      View in: PubMed
    93. Davis DR, Brion JP, Couck AM, Gallo JM, Hanger DP, Ladhani K, Lewis C, Miller CC, Rupniak T, Smith C, et al. The phosphorylation state of the microtubule-associated protein tau as affected by glutamate, colchicine and beta-amyloid in primary rat cortical neuronal cultures. Biochem J. 1995 Aug 1; 309 ( Pt 3):941-9.
      View in: PubMed
    94. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995 Jun; 108 ( Pt 6):2241-51.
      View in: PubMed
    95. Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):6-11.
      View in: PubMed
    96. Latimer DA, Gallo JM, Lovestone S, Miller CC, Reynolds CH, Marquardt B, Stabel S, Woodgett JR, Anderton BH. Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. FEBS Lett. 1995 May 22; 365(1):42-6.
      View in: PubMed
    97. Devineni D, Gallo JM. Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May; 28(5):351-60.
      View in: PubMed
    98. Anderton BH, Brion JP, Couck AM, Davis DR, Gallo JM, Hanger DP, Ladhani K, Latimer DA, Lewis C, Lovestone S, et al. Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiol Aging. 1995 May-Jun; 16(3):389-97; discussion 398-402.
      View in: PubMed
    99. Qian M, O'Dwyer PJ, Gallo JM. High-performance liquid chromatographic method for the determination of AG-331, a novel anti-cancer agent, in human serum and urine using solid-phase extraction and photodiode-array detection. J Chromatogr B Biomed Appl. 1995 Apr 21; 666(2):307-14.
      View in: PubMed
    100. Devineni D, Blanton CD, Gallo JM. Preparation and in vitro evaluation of magnetic microsphere-methotrexate conjugate drug delivery systems. Bioconjug Chem. 1995 Mar-Apr; 6(2):203-10.
      View in: PubMed
    101. Varkonyi P, Bruckner JV, Gallo JM. Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations. J Pharm Sci. 1995 Mar; 84(3):381-4.
      View in: PubMed
    102. Devineni D, Klein-Szanto A, Gallo JM. Tissue distribution of methotrexate following administration as a solution and as a magnetic microsphere conjugate in rats bearing brain tumors. J Neurooncol. 1995; 24(2):143-52.
      View in: PubMed
    103. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol. 1994 Dec 1; 4(12):1077-86.
      View in: PubMed
    104. Dallas CE, Muralidhara S, Chen XM, Ramanathan R, Varkonyi P, Gallo JM, Bruckner JV. Use of a physiologically based model to predict systemic uptake and respiratory elimination of perchloroethylene. Toxicol Appl Pharmacol. 1994 Sep; 128(1):60-8.
      View in: PubMed
    105. Shanmuganathan K, Koudriakova T, Nampalli S, Du J, Gallo JM, Schinazi RF, Chu CK. Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. J Med Chem. 1994 Mar 18; 37(6):821-7.
      View in: PubMed
    106. Waleh NS, Gallo J, Grant TD, Murphy BJ, Kramer RH, Sutherland RM. Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma. Cancer Res. 1994 Feb 1; 54(3):838-43.
      View in: PubMed
    107. Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol. 1994; 33(6):484-8.
      View in: PubMed
    108. Brion JP, Smith C, Couck AM, Gallo JM, Anderton BH. Developmental changes in tau phosphorylation: fetal tau is transiently phosphorylated in a manner similar to paired helical filament-tau characteristic of Alzheimer's disease. J Neurochem. 1993 Dec; 61(6):2071-80.
      View in: PubMed
    109. Gallo JM, Cheung LL, Kim HJ, Bruckner JV, Gillespie WR. A physiological and system analysis hybrid pharmacokinetic model to characterize carbon tetrachloride blood concentrations following administration in different oral vehicles. J Pharmacokinet Biopharm. 1993 Oct; 21(5):551-74.
      View in: PubMed
    110. Gallo JM, Varkonyi P, Hassan EE, Groothius DR. Targeting anticancer drugs to the brain: II. Physiological pharmacokinetic model of oxantrazole following intraarterial administration to rat glioma-2 (RG-2) bearing rats. J Pharmacokinet Biopharm. 1993 Oct; 21(5):575-92.
      View in: PubMed
    111. Hassan EE, Gallo JM. Targeting anticancer drugs to the brain. I: Enhanced brain delivery of oxantrazole following administration in magnetic cationic microspheres. J Drug Target. 1993; 1(1):7-14.
      View in: PubMed
    112. Gallo JM, Swagler AR, Mehta M, Qian M. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. VI. Effect of the calcium channel blocker nimodipine on zidovudine kinetics in monkeys. J Pharmacol Exp Ther. 1993 Jan; 264(1):315-20.
      View in: PubMed
    113. Hassan EE, Gallo JM. High-performance liquid chromatographic analysis of the anticancer drug oxantrazole in rat whole blood and tissues. J Chromatogr. 1992 Nov 6; 582(1-2):225-31.
      View in: PubMed
    114. Qian M, Gallo JM. High-performance liquid chromatographic determination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr. 1992 Jul 24; 578(2):316-20.
      View in: PubMed
    115. Qian M, Swagler AR, Fong KL, Crysler CS, Mehta M, Gallo JM. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys. Drug Metab Dispos. 1992 May-Jun; 20(3):396-401.
      View in: PubMed
    116. Hassan EE, Parish RC, Gallo JM. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm Res. 1992 Mar; 9(3):390-7.
      View in: PubMed
    117. Qian MX, Swagler AR, Mehta M, Vishwanathan CT, Gallo JM. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys. Pharm Res. 1992 Feb; 9(2):224-7.
      View in: PubMed
    118. Davis EL, Wieczkowski G, Yu XY, Joynt RB, Gallo J. Adhesion of dentin bonding agents after smear layer treatments. Am J Dent. 1992 Feb; 5(1):29-32.
      View in: PubMed
    119. Gallo JM, Finco TS, Swagler AR, Mehta MU, Viswanathan CT, Qian M. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys. AIDS Res Hum Retroviruses. 1992 Feb; 8(2):277-83.
      View in: PubMed
    120. Gallo JM, Sanzgiri Y, Howerth EW, Finco TS, Wilson J, Johnston J, Tackett R, Budsberg SC. Zidovudine serum, cerebrospinal fluid, and brain concentrations following chronic administration of a new zidovudine formulation via an implantable pump in dogs [corrected]. J Pharm Sci. 1992 Jan; 81(1):11-5.
      View in: PubMed
    121. Qian MX, Finco TS, Mehta M, Viswanathan CT, Gallo JM. Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys. J Pharm Sci. 1991 Nov; 80(11):1007-11.
      View in: PubMed
    122. Graham-Pole J, Gee A, Emerson S, Gallo J, Lee C, Luzins J, Janssen WE, Pick T, Worthington-White D, Elfenbein G, et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood. 1991 Sep 15; 78(6):1607-14.
      View in: PubMed
    123. Hanger DP, Brion JP, Gallo JM, Cairns NJ, Luthert PJ, Anderton BH. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated. Biochem J. 1991 Apr 1; 275 ( Pt 1):99-104.
      View in: PubMed
    124. Gallo JM, Lam FC, Perrier DG. Moment method for the estimation of mass transfer coefficients for physiological pharmacokinetic models. Biopharm Drug Dispos. 1991 Mar; 12(2):127-37.
      View in: PubMed
    125. Gallo JM, Etse JT, Doshi KJ, Boudinot FD, Chu CK. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm Res. 1991 Feb; 8(2):247-53.
      View in: PubMed
    126. Qian MX, Finco TS, Gallo JM. Rapid and simultaneous determination of zidovudine and its glucuronide metabolite in plasma and urine. Application to the pharmacokinetic interaction of zidovudine and probenecid in the monkey. J Pharm Biomed Anal. 1991; 9(3):275-9.
      View in: PubMed
    127. Chu CK, Bhadti VS, Doshi KJ, Etse JT, Gallo JM, Boudinot FD, Schinazi RF. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. J Med Chem. 1990 Aug; 33(8):2188-92.
      View in: PubMed
    128. Hassan EE, Gallo JM. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm Res. 1990 May; 7(5):491-5.
      View in: PubMed
    129. Sanzgiri YD, Blanton CD, Gallo JM. Synthesis, characterization, and in vitro stability of chitosan-methotrexate conjugates. Pharm Res. 1990 Apr; 7(4):418-21.
      View in: PubMed
    130. Patel BA, Boudinot FD, Schinazi RF, Gallo JM, Chu CK. Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species. J Pharmacobiodyn. 1990 Mar; 13(3):206-11.
      View in: PubMed
    131. Kim HJ, Bruckner JV, Dallas CE, Gallo JM. Effect of dosing vehicles on the pharmacokinetics of orally administered carbon tetrachloride in rats. Toxicol Appl Pharmacol. 1990 Jan; 102(1):50-60.
      View in: PubMed
    132. Doshi KJ, Gallo JM, Boudinot FD, Schinazi RF, Chu CK. Comparative pharmacokinetics of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZddU) in mice. Drug Metab Dispos. 1989 Nov-Dec; 17(6):590-4.
      View in: PubMed
    133. Gallo JM, Hung CT, Gupta PK, Perrier DG. Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat. J Pharmacokinet Biopharm. 1989 Jun; 17(3):305-26.
      View in: PubMed
    134. Gallo JM, Gupta PK, Hung CT, Perrier DG. Evaluation of drug delivery following the administration of magnetic albumin microspheres containing adriamycin to the rat. J Pharm Sci. 1989 Mar; 78(3):190-4.
      View in: PubMed
    135. Ferrante FM, Orav EJ, Rocco AG, Gallo J. A statistical model for pain in patient-controlled analgesia and conventional intramuscular opioid regimens. Anesth Analg. 1988 May; 67(5):457-61.
      View in: PubMed
    136. Gallo JM, Hassan EE. Receptor-mediated magnetic carriers: basis for targeting. Pharm Res. 1988 May; 5(5):300-4.
      View in: PubMed
    137. Gallo JM, Précigout E, Schrével J. Subcellular sequestration of an antigenically unique beta-tubulin. Cell Motil Cytoskeleton. 1988; 9(2):175-83.
      View in: PubMed
    138. Gallo JM, Lam FC, Perrier DG. Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm. 1987 Jun; 15(3):271-80.
      View in: PubMed
    139. Gallo JM, Escalier D, Schrével J, David G. Differential distribution of tubulin epitopes in human spermatozoa. Eur J Cell Biol. 1986 Mar; 40(1):111-6.
      View in: PubMed
    140. Gallo JM, Gall EP, Gillespie WR, Albert KS, Perrier D. Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol. 1986 Jan; 26(1):65-70.
      View in: PubMed
    141. Gallo JM, Hung CT, Perrier DG. Reversed-phase ion-pair high-performance liquid chromatography of adriamycin and adriamycinol in rat serum and tissues. J Pharm Biomed Anal. 1986; 4(4):483-90.
      View in: PubMed
    Gallo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067